Legal & General Group Plc Acquires Shares of 36,419 Personalis, Inc. $PSNL

Legal & General Group Plc acquired a new stake in Personalis, Inc. (NASDAQ:PSNL) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 36,419 shares of the company’s stock, valued at approximately $488,000.

Several other institutional investors have also modified their holdings of the company. The Manufacturers Life Insurance Company acquired a new position in shares of Personalis during the second quarter worth $248,000. Quantbot Technologies LP acquired a new stake in Personalis in the second quarter valued at $69,000. Ieq Capital LLC acquired a new stake in Personalis in the second quarter valued at $366,000. Green Alpha Advisors LLC purchased a new stake in Personalis during the 2nd quarter worth about $904,000. Finally, AlpInvest Partners B.V. acquired a new position in shares of Personalis during the 2nd quarter worth about $505,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on PSNL shares. TD Cowen reiterated a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Needham & Company LLC cut Personalis from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Morgan Stanley upped their price target on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Lake Street Capital cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price objective on the stock. in a report on Monday, July 20th. Four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $14.54.

Personalis Price Performance

Shares of NASDAQ:PSNL opened at $16.60 on Wednesday. The stock has a market cap of $1.74 billion, a P/E ratio of -15.23 and a beta of 2.31. The firm has a fifty day moving average price of $14.68 and a 200 day moving average price of $10.41. Personalis, Inc. has a 1-year low of $4.95 and a 1-year high of $18.89.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The business had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Sell-side analysts expect that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Insider Transactions at Personalis

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the completion of the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,558,668.88. This represents a 29.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,620,618.94. The trade was a 20.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 256,233 shares of company stock worth $3,568,236. Corporate insiders own 4.20% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.